Investigational Drug Shows Promise in Reducing Lupus Activity in Phase 2 Trial

Johnson & Johnson's experimental drug, nipocalimab, achieved its primary goal in a Phase 2 study for systemic lupus erythematosus (SLE). The trial demonstrated a notable and sustained reduction in disease activity over 52 weeks. This marks the first FcRn blocker to be studied for SLE, offering a new approach to target pathogenic autoantibodies.